Please note: The information displayed on this page might be outdated.
Saniona: A research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix, S.A and Luc Therapeutics, Inc.
Based in...
Europe, Public
Market Cap
100MM - 500MM
Ballerup, Hovedstaden

Company Participants at Winter Private Company Showcase

Juanita do Couto
Juanita do Couto is an executive assistant at Saniona. Previously she worked for Parexel (2014-2020) and as an executive assistant for Alliance Energy (2013).
Rami Levin
Saniona, President/CEO
Rami Levin is a seasoned biotech leader with over 24 years of experience in rare diseases and central nervous system disorders. Prior to joining Saniona in January 2020, he most recently served as President of Sobi Inc., the North American affiliate of international rare disease company Sobi. At Sobi, he built and led the North American organization from infancy to a team of approximately 300 employees generating over half a billion USD in annual revenue. Levin’s experience in mergers and acquisitions resulted in the successful acquisitions of Gamifant, the first FDA approved treatment for primary hemophagocytic lymphohistiocytosis (pHLH), and Synagis, the only FDA approved prophylaxis for respiratory syncytial virus (RSV). Under his leadership, the Sobi team launched Gamifant and integrated the entire Synagis sales and medical organizations, retaining 100% of the team. Prior to joining Sobi, Levin held commercial leadership roles of increasing strategic importance for 16 years at Merck Serono in a number of countries, including the U.S., Sweden, Switzerland and Israel. Levin earned his MBA from the Recanati Business School at Tel Aviv University in Israel, majoring in International Marketing, and has a BSc in Biology from Tel Aviv University. In addition to his current position as President and CEO of Saniona, Levin serves as a member of the Board of Advisors for Life Science Cares. Levin holds 0 shares and 710,313 warrants in the warrant program 2020/2024 and 1,262,000 warrants in the warrant program 2020/2031.

Upcoming Company Event Participation

Top 10 Holders of Saniona AB

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
RA Capital Management LP 41.50 11,792,452 26.16 Stakes 8/14/20
Fjärde AP-fonden 6.64 1,886,792 4.18 Stakes 9/30/20
Arctic Fund Management AS (Sweden) 3.51 998,469 2.21 Funds 11/30/20
Nordea Investment Management AB 2.74 778,259 1.73 Stakes 9/30/20
SEB Investment Management AB 0.81 229,883 0.51 Funds 8/31/20
Handelsbanken Fonder AB 0.54 154,508 0.34 Funds 11/30/20
Skandia Investment Management AB 0.20 57,266 0.13 Funds 11/30/20
Storebrand Asset Management AS 0.11 31,002 0.07 Funds 11/30/20
Catella Fondförvaltning AB 0.02 5,318 0.01 Funds 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.